Detecting Cancer Patents (Class 435/6.14)
-
Patent number: 9567641Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.Type: GrantFiled: July 3, 2014Date of Patent: February 14, 2017Assignees: SAMSUNG ELECTRONICS CO., LTD., GEORGETOWN UNIVERSITYInventors: Bo Gyou Kim, Shangzi Wang, Ji Min Lee, Kyung Ah Kim, Louis M. Weiner
-
Patent number: 9556491Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.Type: GrantFiled: February 26, 2008Date of Patent: January 31, 2017Assignee: JOHN WAYNE CANCER INSTITUTEInventor: Dave S. B. Hoon
-
Patent number: 9551036Abstract: Aspects of the invention relate to methods and compositions for characterizing or modulating the expression of metabolic mesenchymal genes. In some embodiments, methods for assessing the expression of metabolic mesenchymal genes and related gene signatures are provided that are useful for cancer classification, prognosis, diagnosis, or treatment selection.Type: GrantFiled: February 25, 2014Date of Patent: January 24, 2017Assignee: Whitehead Institute for Biomedical ResearchInventors: Yoav D. Shaul, David M. Sabatini
-
Patent number: 9550989Abstract: The present disclosure encompasses methods for rational design of microRNA and small interfering RNA chimeras and compositions and methods of use thereof.Type: GrantFiled: October 3, 2014Date of Patent: January 24, 2017Assignee: WASHINGTON UNIVERSITYInventor: Xiaowei Wang
-
Patent number: 9545630Abstract: Provided is a method for fabricating a microchip for nucleic acid amplification reaction that is capable of simple and highly accurate analysis. Provided is a method for fabricating a microchip for nucleic acid amplification reaction, the method including a solidification step of drying a reagent solution including at least a part of substances required for a nucleic acid amplification reaction, and a containment step of arranging the reagent solution including the solidified substance in wells that serve as a reaction site for a nucleic acid amplification reaction. In the microchip for nucleic acid amplification reaction fabricated by the fabrication method, since substances required for the nucleic acid amplification reaction are contained by being solidified, non-specific amplification is suppressed in a nucleic acid amplification reaction, which enables highly accurate analysis.Type: GrantFiled: January 16, 2013Date of Patent: January 17, 2017Assignee: Sony CorporationInventors: Masahiro Matsumoto, Masaki Sato, Hidetoshi Watanabe
-
Patent number: 9540696Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.Type: GrantFiled: September 23, 2013Date of Patent: January 10, 2017Assignees: Stichting Katholieke Universiteit, The University Medical Centre Nijmegen, The Johns Hopkins UniversityInventors: Marion J. G. Bussemakers, William B. Isaacs
-
Patent number: 9541555Abstract: This invention relates to a screening method for the identification of agents which modulate the activity of a DNA replication protein as a target for intervention in cancer therapy and includes agents which modulate said activity. The invention also relates to the use of the DNA replication protein, and its RNA transcripts in the prognosis and diagnosis of proliferative disease e.g., cancer.Type: GrantFiled: February 5, 2015Date of Patent: January 10, 2017Assignee: Cizzle Biotech LimitedInventor: Dawn Coverley
-
Patent number: 9541545Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: GrantFiled: June 3, 2014Date of Patent: January 10, 2017Assignee: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia
-
Patent number: 9540694Abstract: The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia, in particular breast neoplasia. The invention is based in part on the observation that the basic helix loop helix transcription factor HEYL was found to be overexpressed in breast cancer cells. Accordingly, the invention provides therapeutic compositions and methods for altering the levels and expression of HEYL of the invention, thereby treating a neoplasia, as well as compositions and methods for diagnosing a neoplasia.Type: GrantFiled: May 21, 2007Date of Patent: January 10, 2017Assignee: The Johns Hopkins UniversityInventors: Saraswati Sukumar, Liangfeng Han
-
Patent number: 9534256Abstract: The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.Type: GrantFiled: January 6, 2012Date of Patent: January 3, 2017Assignees: Wake Forest University Health Sciences, The Johns Hopkins UniversityInventors: Jianfeng Xu, William B. Isaacs, Henrik Grönberg
-
Patent number: 9527916Abstract: The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 5, 6 and 7, or a variant of any of said sequences; and/or an antibody light chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 8, 9 and 10, or a variant of any of said sequences.Type: GrantFiled: December 19, 2012Date of Patent: December 27, 2016Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Winfried Robert Mulder, Jannetje Geertruida Borst, Aartje Maria Elizabeth Veraar, Paul Maria Frederikus Vink
-
Patent number: 9528111Abstract: The invention provides a single-stranded nucleic acid molecule containing an expression inhibitory sequence that inhibits expression of a target gene, region (X), linker region (Lx), and region (Xc), wherein the linker region (Lx) is linked between the region (Xc) and the region (Xc), the region (Xc) is complementary to the region (X), at least one of the region (X) and the region (Xc) contains the expression inhibitory sequence, and the linker region (Lx) contains an atomic group derived from an amino acid. The single-stranded nucleic acid molecule can inhibit expression of the target gene.Type: GrantFiled: December 29, 2012Date of Patent: December 27, 2016Assignee: Bonac CorporationInventors: Tadaaki Ohgi, Hiroshi Suzuki, Tomohiro Hamasaki, Eriko Aoki
-
Patent number: 9522171Abstract: The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus (SARS), pandemic Influenza A H5N1 (avian influenza) and pandemic influenza A H1N1 (swine 'flu).Type: GrantFiled: January 2, 2015Date of Patent: December 20, 2016Assignee: Volution Immuno Pharmaceuticals SAInventor: Wynne Weston-Davies
-
Patent number: 9518297Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.Type: GrantFiled: June 13, 2012Date of Patent: December 13, 2016Assignee: Gendiag.exe, S.L.Inventors: Eduardo Salas, José Manuel Soria, Miroslava Ogorelkova, Roberto Elosua Llanos, Joan Vila, Sergio Castillo
-
Patent number: 9518125Abstract: Provided is method of diagnosing liver cancer in a subject, the method comprising contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2), cluster of differentiation 43 (CD43), or any combination thereof on the surface of a microvesicle; and measuring the level of the substance bound to microvesicles in the sample; and related methods and compositions.Type: GrantFiled: July 2, 2014Date of Patent: December 13, 2016Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Ye-ryoung Yong, Hyun-ju Kang, Ga-hee Kim, Kyung-hee Park, Jong-myeon Park
-
Patent number: 9512235Abstract: The present invention relates to an antibody being capable of binding specifically to BC200 RNA or its antigen binding fragment, a polynucleotide of encoding the antibody or its antigen binding fragment, a composition, kit and method for detecting BC200 RNA in a sample using the antibody or its antigen binding fragment, and a composition for diagnosis, prevention or treatment of BC200 RNA-associated diseases including the antibody or its antigen binding fragment.Type: GrantFiled: June 12, 2014Date of Patent: December 6, 2016Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Younghoon Lee, Euihan Jung, Jung Min Lee, Insoo Park, Hyo Jeong Hong
-
Patent number: 9512444Abstract: The present invention provides methods and kits for editing specific chromosomal sequences in cells. In particular, targeting endonucleases and single-stranded nucleic acids are used to edit the chromosomal sequence.Type: GrantFiled: July 22, 2011Date of Patent: December 6, 2016Assignee: Sigma-Aldrich Co. LLCInventors: Fuqiang Chen, Shondra M. Pruett-Miller, Gregory D. Davis
-
Patent number: 9506062Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.Type: GrantFiled: August 24, 2015Date of Patent: November 29, 2016Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
-
Patent number: 9493804Abstract: The present invention relates to a nucleic acid molecule for recombinant expression and secretion of a peptide or protein of interest comprising a hemolysin A and/or hemolysin C-derived nucleotide sequence, fragments thereof, homologs thereof, or the complements thereof, and a nucleotide sequence encoding the peptide or protein of interest.Type: GrantFiled: October 22, 2012Date of Patent: November 15, 2016Assignee: Heinrich-Heine-Universitaet DuesseldorfInventors: Christian Schwarz, Lutz Schmitt, Sander Hendrikus Joannes Smits
-
Patent number: 9493842Abstract: Disclosed are methods of determining the prognosis of thymic cancer in a subject comprising detecting a mutation in the general transcription factor IIi (GTF2I) genetic sequence or protein. The presence of a GTF2I mutation indicates that the thymic cancer is indolent.Type: GrantFiled: April 2, 2015Date of Patent: November 15, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Giuseppe Giaccone, Yisong Wang, Iacopo Petrini
-
Patent number: 9486449Abstract: The subject invention provides for cancer therapy.Type: GrantFiled: April 7, 2014Date of Patent: November 8, 2016Inventor: Malka Cohen-Armon
-
Patent number: 9487493Abstract: The present invention provides methods for treating muscle atrophy by administering a PPAR? agonist.Type: GrantFiled: September 5, 2014Date of Patent: November 8, 2016Assignee: vTv Therapeutics LLCInventors: Maria Carmen Valcarce Lopez, Eliot Ohlstein
-
Patent number: 9486545Abstract: The present invention relates to biomarkers for colon cancers, specifically adenomas and adenocarcinomas in the GI tract. The inventors have discovered that the expression and/or overexpression of biomarkers such as CLDN1, GPR56, GRM8, LY6G6D, TLR4 and SLCO1B3 are indicative of adenomas and adenocarcinomas. A method of detecting colon cancer using targeted molecular imaging agents is also presented.Type: GrantFiled: September 30, 2013Date of Patent: November 8, 2016Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: David L. Morse, Robert J. Gillies
-
Patent number: 9481890Abstract: A method of modifying morphology in a plant comprising introducing into a plant at least one chimaeric gene comprising a promoter sequence operably associated with a nucleic acid sequence, the promoter sequence being operable to direct expression in specific cells of the plant and the nucleic acid sequence encoding at least one gene product capable of altering the metabolism of or causing death of the specific cells and/or nearby cells. In particular, the promoter sequence is operable to direct expression in lateral bud or lateral shoot and the nucleic acid encoding at least one gene product capable of disrupting the metabolism of or causing the death of the lateral bud or lateral shoot or nearby cells. Preferably the promoter sequence comprises the sequence shown as SEQ ID No. 1 or SEQ ID No. 7 or SEQ ID No. 4, or a part thereof capable of regulating expression of a gene, or a sequence having at least 60%, preferably at least 75%, homology to SEQ ID No. 1 or SEQ ID No.Type: GrantFiled: September 30, 2013Date of Patent: November 1, 2016Assignee: British American Tobacco (Investments) LimitedInventors: Christopher John Robert Thomas, Martin Richard Ward
-
Patent number: 9481885Abstract: The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Tolllike receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.Type: GrantFiled: December 13, 2012Date of Patent: November 1, 2016Assignee: Ohio State Innovation FoundationInventors: Carlo M. Croce, Muller Fabbri
-
Patent number: 9469875Abstract: The present invention relates generally to the detection or diagnosis of depressive disorders, and provides methods and compositions useful for this purpose. In particular, the present invention provides biomarkers for the detection or diagnosis of major depressive disorder, and methods of use thereof.Type: GrantFiled: January 13, 2016Date of Patent: October 18, 2016Assignee: Northwestern UniversityInventors: Eva Redei, Brian Andrus
-
Patent number: 9458456Abstract: Some embodiments of the present technology relate to methods and compositions for the diagnosis and treatment of cancer. Some embodiments include methods and compositions for the diagnosis and treatment of castration-resistant prostate cancer. Some embodiments include methods and compositions for the diagnosis and treatment of pancreatic cancer.Type: GrantFiled: March 30, 2012Date of Patent: October 4, 2016Assignee: UNIVERSITY OF SOUTH ALABAMAInventors: Ajay Pratap Singh, Sanjeev Srivastava, Seema Singh
-
Patent number: 9447146Abstract: Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.Type: GrantFiled: October 18, 2013Date of Patent: September 20, 2016Assignee: Thomas Jefferson UniversityInventors: Hank Wolfe, Scott A. Waldman
-
Patent number: 9447471Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.Type: GrantFiled: December 27, 2012Date of Patent: September 20, 2016Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
-
Patent number: 9441046Abstract: Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.Type: GrantFiled: August 7, 2014Date of Patent: September 13, 2016Assignee: ASTRAZENECA ABInventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
-
Patent number: 9441047Abstract: Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.Type: GrantFiled: August 7, 2014Date of Patent: September 13, 2016Assignee: ASTRAZENECA ABInventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
-
Patent number: 9441037Abstract: Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.Type: GrantFiled: August 7, 2014Date of Patent: September 13, 2016Assignee: ASTRAZENECA ABInventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
-
Patent number: 9435001Abstract: The invention describes a consensus PCR based method (i.e. HRE7-PCR) for the simultaneous detection of 14 Human Papilloma Virus types (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are classified as (probably) high-risk, relating to the causation of cervical cancer) and a candidate hrHPV type (i.e. HPV 67) using sets of 6 overlapping forward primers and 9 overlapping backward primers that together amplify a fragment of about (215) to (245) base pairs of the E7 open reading frame of these hrHPV types. For the detection of reaction products an EIA format can be used with the aid of a cocktail of type-specific oligoprobes as exemplified herein. Furthermore, we have developed a method for an efficient typing of these (15) HPVs that is compatible with the method for detection. This RLB typing system involves hybridization of PCR products with immobilized type-specific oligoprobes.Type: GrantFiled: November 1, 2007Date of Patent: September 6, 2016Assignee: SELF-SCREEN B.V.Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders
-
Patent number: 9434980Abstract: A method is disclosed for concentrating sample constituents and for multiplying nucleic acids from a biological sample which are containing in the sample constituents. The nucleic acids are amplified on the same filter on which the sample constituents are also separated off.Type: GrantFiled: October 27, 2011Date of Patent: September 6, 2016Assignee: ROBERT BOSCH GMBHInventors: Peter Rothacher, Jan Weile, Susanne Muench, Martina Daub
-
Patent number: 9434992Abstract: Provided are a diagnosis marker, a diagnosis method, and a therapeutic agent suitable for diagnosing and treating amyotrophic lateral sclerosis (ALS). Also provided are an animal model and a cell model suitable for developing a therapeutic agent and a treatment method for ALS. The diagnosis method for ALS includes: an isolation step in which a nucleic acid is isolated from a specimen taken from a subject; a detection step in which bases expressed in a human chromosome 10 optineurin (OPTN) gene region are detected from the isolated nucleic acid; and a determination step in which it is determined whether or not the detected bases are mutated.Type: GrantFiled: March 3, 2014Date of Patent: September 6, 2016Assignee: HIROSHIMA UNIVERSITYInventors: Hideshi Kawakami, Hirofumi Maruyama, Hiroyuki Morino
-
Patent number: 9428845Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: GrantFiled: December 27, 2011Date of Patent: August 30, 2016Assignee: Warp Drive Bio, Inc.Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
-
Patent number: 9422606Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.Type: GrantFiled: October 21, 2010Date of Patent: August 23, 2016Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATEDInventor: Feras Hantash
-
Patent number: 9422551Abstract: An improved adapter design for ligation to target RNA in a library is described which enables target RNAs that would normally be under-represented or not represented at all in a cDNA library or a PCR product of the cDNA library, to be represented with average frequency.Type: GrantFiled: May 29, 2013Date of Patent: August 23, 2016Assignee: New England Biolabs, Inc.Inventors: G. Brett Robb, Ryan T. Fuchs, Fanglei Zhuang
-
Patent number: 9416410Abstract: The present invention is related to an improved method for HER2 gene test by using quantitative real-time PCR (Polymerase Chain Reaction) technique. Our invention streamlines test process, and incorporates quality control for each major step, including sample, reagent, operation, and data report. We eliminate the need for reference genes which is hard to standardize in HER2 PCR test. We develop a cutoff reference point by using the statistical mean of tumor tissue population, and adopt a simplified scoring scheme for evaluation of HER2 status. Our invention produces consistent result across machines and labs, and has proven to be clinically successful in HER2 test.Type: GrantFiled: February 13, 2013Date of Patent: August 16, 2016Assignee: Genetics Development CorporationInventors: Rong Yu, Kung-ying Chiu, Shau-zou Lu
-
Patent number: 9403141Abstract: De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.Type: GrantFiled: October 16, 2015Date of Patent: August 2, 2016Assignee: TWIST BIOSCIENCE CORPORATIONInventors: William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle
-
Patent number: 9382537Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.Type: GrantFiled: August 13, 2014Date of Patent: July 5, 2016Assignee: ASURAGEN, INC.Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
-
Patent number: 9371565Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: January 26, 2015Date of Patent: June 21, 2016Assignee: Celera CorporationInventors: Ann Begovich, Ellen Beasley, Michelle Cargill, Steven Schrodi
-
Patent number: 9340830Abstract: A method of analyzing a tumor sample comprising: (a) acquiring a library comprising a plurality of tumor members from a tumor sample; (b) contacting the library with a bait set to provide selected members; (c) acquiring a read for a subgenomic interval from a tumor member from said library; (d) aligning said read; and (e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.Type: GrantFiled: December 29, 2011Date of Patent: May 17, 2016Assignee: FOUNDATION MEDICINE, INC.Inventors: Doron Lipson, Geoffrey Alan Otto, Alexander N. Parker, Philip James Stephens, Sean R. Downing, Mima Jarosz, Mikhail G. Shapiro, Roman Yelensky
-
Patent number: 9336298Abstract: Embodiments of the present invention relate to systems, methods, and computer-storage media for a method of contextually analyzing terms within a search query. In one embodiment, a received search query is classified into a domain category. Additionally, information is assigned to a schema associated with the domain by analyzing the search query. Further, at least one search result that helps a user complete a task within the domain is provided based on the information in the schema.Type: GrantFiled: June 16, 2011Date of Patent: May 10, 2016Assignee: Microsoft Technology Licensing, LLCInventors: Shipeng Li, Ye-Yi Wang, Xiaochuan Ni, Jian-Tao Sun, Zheng Chen, Zhimin Zhang, Xiaolong Li, Xuedong Huang, Li Jiang
-
Patent number: 9328383Abstract: The invention relates to a method for the high throughput discovery, detection and genotyping of one or more genetic markers in one or more samples, comprising the steps of restriction endonuclease digest of DNA, adaptor-ligation, optional pre-amplification, selective amplification, pooling of the amplified products, sequencing the libraries with sufficient redundancy, clustering followed by identification of the genetic markers within the library and/or between libraries and determination of (co-)dominant genotypes of the genetic markers.Type: GrantFiled: April 29, 2015Date of Patent: May 3, 2016Assignee: Keygene N.V.Inventors: Michael Josephus Theresia Van Eijk, Anker Preben Sørensen, Marco Gerardus Maria Van Schriek
-
Patent number: 9314434Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.Type: GrantFiled: December 15, 2014Date of Patent: April 19, 2016Assignee: Nogra Pharma LimitedInventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
-
Patent number: 9297012Abstract: Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.Type: GrantFiled: August 18, 2015Date of Patent: March 29, 2016Assignee: The Ohio State University Research FoundationInventor: Carlo M. Croce
-
Patent number: 9296783Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.Type: GrantFiled: September 12, 2013Date of Patent: March 29, 2016Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
-
Patent number: 9297038Abstract: Disclosed are a method and a kit for the quantification of nucleic acids, especially a trace amount of nucleic acid, such as host cell nucleic acid impurities, using real-time PCR with a random primer.Type: GrantFiled: November 9, 2011Date of Patent: March 29, 2016Assignee: KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCEInventors: In Chul Yang, Min Jung Kang, Han Nah Yu, Sang Ryoul Park, Sook Kyoung Kim
-
Patent number: 9238817Abstract: The present invention relates to a method for producing a protein of interest containing one or more disulfide bonds in its native state. The method comprises that a prokaryotic host cell is genetically engineered to express the protein of interest and a sulfhydryl oxidase in the cytoplasm of the host cell. The protein of interest is formed in a soluble form and contains disulfide bonds due to the presence of the sulfhydryl oxidase in the cytoplasm of said host cell. The present invention relates also to a prokaryotic host cell and a vector system for producing a protein of interest containing natively folded disulfide bonds.Type: GrantFiled: December 2, 2011Date of Patent: January 19, 2016Assignee: Univeristy of OuluInventor: Lloyd Ruddock